Patents by Inventor Klaus Giese

Klaus Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11578328
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: February 14, 2023
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20210261980
    Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?->3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3?UTR, wherein the 5? UTR is selected from the group comprising a 5? UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 26, 2021
    Inventors: Klaus GIESE, Oliver KEIL, Jörg KAUFMANN
  • Publication number: 20210062198
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 4, 2021
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 10774332
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 15, 2020
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20190390201
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 3, 2019
    Publication date: December 26, 2019
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 10329568
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10323246
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 10266829
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 23, 2019
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20190024089
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20180291381
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 11, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20180223286
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 15, 2017
    Publication date: August 9, 2018
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 9790501
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9790505
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 17, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9783802
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 10, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Patent number: 9758784
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: September 12, 2017
    Assignee: Silence Therapeutics GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Publication number: 20170247698
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 31, 2017
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20170247707
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20170247697
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 8, 2017
    Publication date: August 31, 2017
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Publication number: 20170247691
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Applicant: Silence Therapeutics GMBH
    Inventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
  • Patent number: 9695423
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 4, 2017
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese